Given that there may be unknown risks of increasing the total therapeutic dose of αPD-L1, we treated tumor-carrying mice with high-dose and low-frequency αPD-L1 to keep the total dose of αPD-L1 unchanged throughout the treatment, supplying more TEV-free αPD-L1 for the blockade of tumor PD-L1 in each administration. The gene discussed is CD274; the disease is neoplasm.